Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
#2PRI RANKED
Most Cited Paper
in Estrogen and related hormone effects
18 Months Post-Publication
Class of 2026
“Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Camizestrant · selective estrogen receptor degrader · fulvestrant · estrogen receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · menopause · SERENA-2 · phase 2 trial · multi-dose comparison · selective estrogen receptor degrader
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459